查詢結果分析
相關文獻
- Surgical Excision of the Tendon Xanthoma in Familial Hypercholesterolemia--a Case Report
- The Mutation Underlying Familial Hypercholesterolemia in a Taiwanese Family
- Familial Hypercholesterolemia and Xanthomatosis Associated with Diabetes Mellitus: A Case Report and Review of the Literature
- 罕病用藥--Lomitapide
- 家族性高膽固醇血症的藥物治療
- 臺灣家族性高膽固醇血症病患的基因診斷和治療
- Short-term Follow-up Results of Drug-eluting Stenting in Premature Coronary Artery Disease Patients with Multiple Atherosclerotic Risk Factors
- Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in High-Risk Adults: The Current Guidelines and New Drugs
- 家族性高膽固醇血症的診斷與治療新進展
- 新收細胞--『家族性高膽固醇血症』細胞株介紹
頁籤選單縮合
題名 | 家族性高膽固醇血症的藥物治療=Therapeutic Management of Familial Hypercholesterolemia |
---|---|
作者 | 吳俊男; 蔡敏鈴; | 書刊名 | 藥學雜誌 |
卷期 | 32:4=129 2016.12[民105.12] |
頁次 | 頁87-92 |
分類號 | 415.38 |
關鍵詞 | 家族性高膽固醇血症; Familial hypercholesterolemia; Low-density lipoprotein cholesterol; Proprotein convertase subtilisin/kexin type 9 inhibitors; |
語文 | 中文(Chinese) |
中文摘要 | 家族性高膽固醇血症 (Familial Hypercholesterolemia, FH) 是屬於體染色體顯 性遺傳疾病,發病特色是血液中的低密度脂蛋白膽固醇 (low-density lipoprotein cholesterol, LDL-C) 會顯著升高,並出現早發性動脈粥樣硬化心血管疾病 (premature atherosclerotic cardiovascular disease) 的風險性。早期積極診斷與治療,可以降低心臟 冠狀動脈疾病的風險。目前臨床上治療首選是給予高強度的史他汀 (statin) 類藥物, 需要時,可再合併使用可抑制腸胃道吸收膽固醇的 ezetimibe 藥物。對於治療效果 不佳的病人,新一代降血脂藥物是需要的。新型藥物如雨後春筍般出現,目前都己 經被美國食品和藥物管理局核准上市,包括了 mipomersen (表面脂蛋白寡核苷酸抑 制劑)、lomitapide (微粒體三酸甘油酯轉移蛋白抑制劑) 和 alirocumab 及 evolocumab (Proprotein convertase subtilisin/kexin type 9 (PCSK9) 抑制劑),皆有不錯的療效。本文 將綜述目前新的治療藥物,供大家參考。 |
英文摘要 | Familial hypercholesterolaemia (FH) is an autosomal inherited disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) concentrations and an increased risk of premature atherosclerotic cardiovascular disease. Although FH is one of the most common genetic disorders, this disorder remains mostly undetected and its management is often suboptimal. Early and aggressive treatment can prevent premature atherosclerotic cardiovascular disease in these high-risk patients. High-intensity statin therapy is currently an established treatment of choice for this disease. Some patients as statin monotherapy do not achieve LDL-C target values. Combination therapy to lower LDL-C levels further (such as statins plus ezetimibe) has been successful. Additional treatments are often necessary to achieve appropriate LDL-C lowering in homozygous FH and heterozygous FH who are statinrefractory. Novel drug therapies are continuously emerging. Contemporary therapies including mipomersen, an inhibitor of apolipoprotein B-100 synthesis; lomitapide, a microsomal triglyceride transfer protein inhibitor; and alirocumab and evolocumab, PCSK9 inhibitors, are currently approved by the U.S. Food and Drug Administration for use in FH. The purpose of this article is to provide an overview of the clinical results recently reported for FH treatment. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。